The company's financial stability is increasingly fragile, with total assets contracting from $11.3 million in 2025Q3 to $6.9 million in 2026Q1, alongside an accumulated deficit of $247.9 million.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 6.57M | 8.85M | 8.83M | 9.51M | 13.85M | 26.57M | 19.47M | 7.49M | 10.34M | 9.42M | 10.11M | 7.15M | 6.49M | 7.61M | 3.84M | 7.13M | 8.01M | 7.9M | 1.92M | 2.44M | 304.04K | 1.52M | 3.13M | 4.29M | 4.25M | 10.04M | 13.03M | 8.65M | 15M | 17.4M | 1.07M |
| Cash & Short-Term Investments | 6.03M | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M | 18.68M | 5.42M | 8.98M | 7.81M | 8.77M | 4.92M | 5.53M | 5.86M | 3.36M | 6M | 7.45M | 7.69M | 1.48M | 2.22M | 119.64K | 821.7K | 2.33M | 4.12M | 4.15M | 9.94M | 12.85M | 8.54M | 12.2M | 15.7M | 1.02M |
| Cash Only | 6.03M | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M | 18.68M | 5.42M | 8.98M | 7.81M | 8.77M | 4.92M | 5.53M | 5.86M | 3.36M | 6M | 7.45M | 7.69M | 1.48M | 2.22M | 119.64K | 821.7K | 2.33M | 4.12M | 4.15M | 9.94M | 10.83M | 5M | 12.2M | 15.7M | 1.02M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.01M | 3.55M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 195.15K | 219.33K | 242.72K | 564.87K | 1.46M | 1.2M | 1.34M | 1.21M | 1.99M | 794.77K | 1.62M | 339.31K | 936.63K | 372.65K | 23.63K | 278.32K | 97.84K | 89.93K | 564.33K | 742.99K | 20.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | 320.22 | 2.66K | 106.8 | 166.05 | 83.69 | 90.25 | 42.15 | 82.64 | 41.19 | 183.12 | 39.38 | 44.61 | 69.82 | 3.06 | 43.98 | 28.39 | 14.19 | 66.96 | 271.87 | 91.25 | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.87K | 82.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.54 | 15.9 | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 535.82K | 912.85K | 1.01M | 866.01K | 274.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185.34K | 102.55K | 2.8M | 1.7M | 0 |
| Total Non-Current Assets | 357.39K | 386.51K | 137.85K | 290.01K | 426.56K | 300.41K | 424.23K | 282.04K | 148.99K | 133.85K | 153.33K | 236.1K | 461.46K | 656.38K | 868.72K | 1.09M | 1.26M | 1.48M | 1.44M | 1.35M | 1.1M | 1.85M | 1.93M | 1.96M | 1.59M | 1.01M | 637.87K | 625.83K | 1.2M | 1.7M | 369.25K |
| Property, Plant & Equipment | 326.94K | 354.96K | 115.08K | 241.76K | 359.47K | 128.38K | 251.54K | 161.5K | 19.63K | 37.16K | 26.7K | 47.37K | 51.51K | 23.87K | 12.99K | 15.03K | 20.7K | 21.17K | 21.22K | 25.94K | 29.69K | 44.73K | 50.48K | 60.8K | 262.92K | 365.22K | 384.16K | 448.95K | 500K | 100K | 183.58K |
| Fixed Asset Turnover | 0.00x | - | - | - | 0.70x | 0.26x | 7.67x | 19.91x | 266.93x | 146.17x | 391.32x | 185.11x | 136.73x | 135.08x | 242.02x | 509.78x | 94.11x | 133.01x | 108.87x | 48.49x | 77.90x | 68.77x | 19.76x | 1.38x | - | - | - | - | 0.40x | 1.00x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 23.25K | 19.7K | 46.86K | 73.95K | 126.63K | 188.73K | 409.95K | 632.51K | 855.73K | 1.08M | 1.24M | 1.46M | 1.42M | 1.32M | 1.07M | 1.8M | 1.88M | 1.9M | 1.32M | 639.96K | 253.71K | 176.88K | 400K | 300K | 185.67K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 73.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 30.45K | 31.55K | 22.78K | 48.24K | 67.1K | 172.03K | 172.69K | 100.83K | 82.5K | 22.73K | 0 | 0 | 0 | 0 | -868.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300K | 1.3M | 0 |
| Total Assets | 6.92M | 9.24M | 8.97M | 9.8M | 14.28M | 26.87M | 19.89M | 7.78M | 10.49M | 9.55M | 10.27M | 7.39M | 6.95M | 8.27M | 4.71M | 8.22M | 9.27M | 9.38M | 3.36M | 3.78M | 1.41M | 3.37M | 5.07M | 6.25M | 5.84M | 11.04M | 13.67M | 9.27M | 16.2M | 19.1M | 1.44M |
| Asset Turnover | 0.00x | - | - | - | 0.02x | 0.00x | 0.10x | 0.41x | 0.50x | 0.57x | 1.02x | 1.19x | 1.01x | 0.39x | 0.67x | 0.93x | 0.21x | 0.30x | 0.69x | 0.33x | 1.64x | 0.91x | 0.20x | 0.01x | - | - | - | - | 0.01x | 0.01x | - |
| Asset Growth % | -41.44% | 3% | -8.48% | -31.39% | -46.86% | 35.08% | 155.82% | -25.89% | 9.86% | -6.99% | 38.99% | 6.22% | -15.86% | 75.67% | -42.79% | -11.27% | -1.23% | 179.07% | -11.13% | 168.94% | -58.28% | -33.45% | -18.94% | 7.09% | -47.13% | -19.22% | 47.43% | -42.76% | -15.18% | 1230.39% | - |
| Total Current Liabilities | 3.62M | 3.7M | 4.85M | 6.15M | 16.52M | 6.29M | 6.08M | 6.31M | 4.21M | 3.23M | 2.87M | 7.41M | 7.11M | 10.04M | 1.15M | 1.43M | 1.91M | 1.21M | 1.39M | 1.19M | 2.52M | 1.84M | 2.08M | 1.01M | 1.2M | 3.27M | 2.92M | 1.73M | 1.1M | 600K | 57.48K |
| Accounts Payable | 828.66K | 1.12M | 667.9K | 1.11M | 3.87M | 2.93M | 2.13M | 2.74M | 2.13M | 1.75M | 1.71M | 2.87M | 3M | 1.52M | 1.12M | 1.3M | 1.67M | 844.86K | 1.02M | 847.61K | 2.11M | 1.53M | 1.67M | 531.59K | 698.12K | 856.19K | 642.44K | 496.89K | 500K | 600K | 0 |
| Days Payables Outstanding | 165.32K | - | 2.04K | 546.59 | 2.56K | 1.47K | 426.92 | 279.88 | 168.78 | 148.51 | 73.92 | 152.18 | 206.3 | 218.12 | 158.29 | 225.71 | 373.06 | 207.8 | 196.44 | 327.94 | 392.39 | 270.33 | 650.38 | 2.55K | - | - | -1.49K | -128.81 | -107.35 | -438 | - |
| Short-Term Debt | 117.23K | 0 | 1.37M | 2.25M | 9.9M | 0 | 324.98K | 0 | 0 | 0 | 0 | 292.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 115.95K | 359.07K | 382.12K | 164.75K | 118.79K | 110.34K | 100K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 298.68K | -3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.67M | 488.13K | 336.44K | 2.42M | 336.69K | 302.94K | 0 | 298.17K | 0 | 0 | 0 | 2.43M | 3.79M | 8.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 165K | 100K | 0 | 0 | 2.25M | 2.16M | 1.13M | 500K | 0 | 57.48K |
| Current Ratio | 1.81x | 2.39x | 1.82x | 1.55x | 0.84x | 4.22x | 3.20x | 1.19x | 2.46x | 2.92x | 3.52x | 0.97x | 0.91x | 0.76x | 3.32x | 4.98x | 4.19x | 6.53x | 1.39x | 2.04x | 0.12x | 0.83x | 1.50x | 4.26x | 3.53x | 3.07x | 4.46x | 4.99x | 13.64x | 29.00x | 18.55x |
| Quick Ratio | 1.81x | 2.39x | 1.82x | 1.55x | 0.84x | 4.22x | 3.20x | 1.19x | 2.46x | 2.92x | 3.52x | 0.97x | 0.91x | 0.76x | 3.32x | 4.98x | 4.19x | 6.49x | 1.33x | 2.04x | 0.12x | 0.83x | 1.50x | 4.26x | 3.53x | 3.07x | 4.46x | 4.99x | 13.64x | 29.00x | 18.55x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -194.19 | -136.55 | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 213.43K | 244.12K | 0 | 1.12M | 233.67K | 9.86M | 10.07M | 6.15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 347.85K | 10.4M | 204.16K | 281.9K | 400K | 100K | 0 |
| Long-Term Debt | 213.43K | 0 | 0 | 1.01M | 0 | 9.86M | 9.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 347.85K | 52.1K | 204.16K | 281.9K | 300K | 0 | 0 |
| Capital Lease Obligations | 820.63K | 244.12K | 0 | 111.86K | 233.63K | 0 | 116.3K | 6.15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.35M | 0 | 0 | -100K | 100K | 0 |
| Total Liabilities | 3.83M | 3.94M | 4.85M | 7.27M | 16.75M | 16.15M | 16.15M | 6.32M | 4.21M | 3.23M | 2.87M | 7.41M | 7.11M | 10.04M | 1.15M | 1.43M | 1.91M | 1.21M | 1.39M | 1.19M | 2.52M | 1.84M | 2.08M | 1.01M | 1.55M | 13.67M | 3.12M | 2.02M | 1.5M | 700K | 57.48K |
| Total Debt | 330.66K | 358.14K | 1.48M | 3.49M | 10.24M | 9.96M | 10.51M | 127.22K | 0 | 0 | 0 | 292.72K | 3.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 115.95K | 359.07K | 729.97K | 216.85K | 322.95K | 392.24K | 400K | 0 | 0 |
| Net Debt | -5.7M | -7.58M | -6.33M | -4.95M | -3.12M | -16.08M | -8.17M | -5.29M | -8.98M | -7.81M | -8.77M | -4.63M | -1.74M | -5.86M | -3.36M | -6M | -7.45M | -7.69M | -1.48M | -2.22M | -119.64K | -821.7K | -2.22M | -3.76M | -3.42M | -9.73M | -10.51M | -4.6M | -11.8M | -15.7M | -1.02M |
| Debt / Equity | 0.11x | 0.07x | 0.36x | 1.39x | - | 0.93x | 2.81x | 0.09x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.04x | 0.07x | 0.17x | - | 0.03x | 0.05x | 0.03x | - | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.49x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -156.20x | -17.18x | -13.83x | -1701.39x | - | - | - | - | -886.87x | - | - | - | - | -10285.71x | -2252.43x | -1054.95x | - | - | - | - | - | -409.24x | -409.24x | - | - | - | - | - |
| Total Equity | 3.09M | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M | 3.74M | 1.46M | 6.28M | 6.32M | 7.4M | -18.31K | -153.89K | -1.77M | 3.55M | 6.79M | 7.36M | 8.17M | 1.98M | 2.59M | -1.11M | 1.53M | 2.98M | 5.24M | 4.29M | -2.63M | 10.55M | 7.26M | 14.7M | 18.4M | 1.38M |
| Equity Growth % | -5.15% | 28.51% | 63.26% | 202.09% | -123.04% | 186.56% | 156.79% | -76.8% | -0.63% | -14.57% | 40502.25% | 88.1% | 91.3% | -149.84% | -47.71% | -7.7% | -9.99% | 313.44% | -23.67% | 333.69% | -172.54% | -48.78% | -43.11% | 22.38% | 263.02% | -124.93% | 45.34% | -50.64% | -20.11% | 1235.08% | - |
| Book Value per Share | 0.30 | 1.02 | 2.48 | 5.20 | -13.77 | 57.71 | 32.67 | 18.05 | 114.37 | 246.85 | 495.40 | -1.69 | -16.39 | -274.69 | 47.83 | 92.96 | 109.06 | 2342.86 | 58.22 | 85.69 | -52.16 | 92.19 | 220.32 | 539.20 | 571.49 | -586.43 | 2595.02 | 2024.03 | 4429.04 | 17574.02 | 815.98 |
| Total Shareholders' Equity | 3.09M | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M | 3.74M | 1.46M | 6.28M | 6.32M | 7.4M | -18.31K | -153.89K | -1.77M | 3.55M | 6.79M | 7.36M | 8.17M | 1.98M | 2.59M | -1.11M | 1.53M | 2.98M | 5.24M | 4.29M | -2.63M | 10.55M | 7.26M | 6.3M | 18.4M | 1.38M |
| Common Stock | 10.52K | 10.09K | 2.51K | 10.38K | 2.91K | 2.86K | 30.64K | 21.75K | 17.68K | 8.73K | 5.47K | 31.27K | 23.94K | 19.63K | 11.17K | 11.11K | 216.19K | 185.66K | 118.61K | 95K | 68.86K | 50.61K | 42.22K | 34.89K | 26.8K | 20.95K | 12.86K | 10.88K | 0 | 0 | 5.9K |
| Retained Earnings | -247.88M | -245.05M | -233.97M | -225.7M | -219.56M | -205.77M | -193.21M | -175.53M | -166.17M | -157.27M | -150.12M | -146.88M | -139.05M | -132.34M | -122.28M | -118.12M | -115.74M | -108.35M | -102.32M | -98.9M | -92.73M | -84.57M | -79.85M | -73.98M | -68.69M | -63.72M | -49.09M | -44.29M | -35.3M | -13.5M | -8.26M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -427.7K | -468.27K | -468.27K | -443.75K | -443.75K | -443.75K | -400K | 0 | -443.75K |
| Accumulated OCI | 45.79K | 45.79K | 45.79K | 22.24K | 24.75K | 41.94K | -24.34K | -45.01K | -3.67K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20.02K | -13.28K | -132.6K | 0 | -111.18K | 0 | -68.15K | -141.65K | 386.66K | 1.69M | -4.78K | -649.04K | -900K | -900K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.4M | 0 | 0 |
Liquidity and regulatory insolvency
According to quarterly filings, Soligenix has seen its total assets decline from $11.3 million in 2025Q3 to $6.9 million by 2026Q1, a contraction that highlights the company's inability to replenish its resource base through commercial success while it continues to fund ongoing clinical development programs.
The consistent downward trend in total assets suggests that the company is consuming its capital base to sustain operations without achieving a corresponding increase in value-creating assets. This trajectory implies that the business model remains entirely dependent on external capital infusions to prevent further erosion of its financial foundation.
As reported in recent financial statements, the company's cash position has dwindled to $6.0 million as of 2026Q1, down from $10.5 million in 2025Q3, which significantly constrains the firm's ability to navigate potential regulatory delays or unexpected clinical trial costs without seeking immediate dilutive financing.
While the current ratio of 1.81 appears superficially adequate, the lack of recurring revenue means that this liquidity buffer is rapidly depleting. Investors should monitor the burn rate closely, as the current cash position provides a very narrow margin of safety for a company with high fixed R&D requirements.
Based on the company's balance sheet data, shareholders' equity has experienced significant volatility, dropping to $3.1 million in 2026Q1 from a peak of $7.6 million in 2025Q3, a trend driven by the accumulation of massive retained losses totaling approximately $247.9 million over the firm's history.
The persistent negative retained earnings indicate that the company has failed to generate profitable returns on invested capital, forcing a reliance on equity issuance that dilutes existing shareholders. This structural weakness suggests that the equity base is primarily a reflection of past capital raises rather than accumulated operational value.
Although total debt remains relatively low at $330.7K as of 2026Q1, the D/E ratio has fluctuated wildly, reaching as high as 4.17 in 2024Q1, which indicates that even minor debt obligations can disproportionately impact the company's leverage profile given its extremely thin equity base.
The low absolute debt levels should not be interpreted as financial strength, as the company's primary risk is not insolvency from debt service but rather the exhaustion of cash required to fund operations. The volatility in the D/E ratio serves as a warning that the company's capital structure is highly sensitive to changes in equity valuation and cash reserves.
Quick answers to the most common questions about buying SNGX stock.
As of 2025, Soligenix, Inc. (SNGX) had total assets of $9.2M including $8.8M in current assets.
Soligenix, Inc. (SNGX) carries total debt of $0.4M, offset by $7.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Soligenix, Inc. (SNGX) has total shareholders' equity (book value) of $5.3M ($1.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Soligenix, Inc. (SNGX) reported a current ratio of 2.39x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.